Allogene Therapeutics, Inc.ALLONASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank25
3Y CAGR-16.3%
5Y CAGR-4.9%
Year-over-Year Change
Research and development spending
3Y CAGR
-16.3%/yr
vs +14.0%/yr prior
5Y CAGR
-4.9%/yr
Recent deceleration
Acceleration
-30.3pp
Decelerating
Percentile
P25
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
3 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $150.15M | -21.9% |
| 2024 | $192.30M | -20.8% |
| 2023 | $242.91M | -5.3% |
| 2022 | $256.39M | +16.4% |
| 2021 | $220.18M | +14.1% |
| 2020 | $192.99M | +33.5% |
| 2019 | $144.53M | -4.8% |
| 2018 | $151.86M | - |
| 2017 | $0.00 | - |